公开(公告)号：US20220235060A1

公开(公告)日：2022-07-28

申请号：US17615012

申请日：2020-05-28

Applicant: CHIESI FARMACEUTICI S.p.A.

Inventor： Paolo BRUNO ,  Matteo BIAGETTI ,  Claudio FIORELLI ,  Charles BAKER-GLENN ,  Hervè VAN DE POËL ,  Stephen David PENROSE ,  Roberta LANARO

IPC: C07D487/04 ,  C07D471/04

Abstract: The present invention relates to compounds of formula I inhibiting P2X purinoceptor 3 (hereinafter P2X3 inhibitors); particularly the invention relates to compounds that are pyridopyrimidines derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).

公开(公告)号：US20180354945A1

公开(公告)日：2018-12-13

申请号：US15987277

申请日：2018-05-23

Applicant: CHIESI FARMACEUTICI S.p.A.

Inventor： Carmelida CAPALDI ,  Elisabetta ARMANI ,  Christopher HURLEY ,  Barbara Giuseppina AVITABILE-WOO ,  Roberta LANARO ,  Neil Stuart JENNINGS

IPC: C07D471/04

CPC classification number: C07D471/04 ,  A61P11/00

Abstract: Compounds of formula (I) defined herein are p38 MAPK inhibitors and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.

公开(公告)号：US20230212169A9

公开(公告)日：2023-07-06

申请号：US17615012

申请日：2020-05-28

Applicant: CHIESI FARMACEUTICI S.p.A.

Inventor： Paolo BRUNO ,  Matteo BIAGETTI ,  Claudio FIORELLI ,  Charles BAKER-GLENN ,  Hervè VAN DE POËL ,  Stephen David PENROSE ,  Roberta LANARO

IPC: C07D487/04 ,  C07D471/04

CPC classification number: C07D487/04 ,  C07D471/04

Abstract: The present invention relates to compounds of formula I inhibiting P2X purinoceptor 3 (hereinafter P2X3 inhibitors); particularly the invention relates to compounds that are pyridopyrimidines derivatives, methods of preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. The compounds of the invention may be useful in the treatment of many disorders associated with P2X3 receptors mechanisms, such as respiratory diseases including cough, asthma, idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD).